GlassScriptPhysician profile
Barbara C Jost
NPI 1144243031
$9,431.15
in general payments reported to CMS, 2019-2025
49 companies · $2,500 in 2025
The $2,500 reported for 2025 was more than what 76% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $842 · 2020: $381 · 2021: $845 · 2022: $1,677 · 2023: $1,636 · 2024: $1,549 · 2025: $2,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,817 · Travel and Lodging: $769 · Consulting Fee: $64.78 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,817.29 |
| Travel and Lodging | $769.41 |
| Consulting Fee | $64.78 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,512.26 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Insmed, INC. | $1,115.67 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $815.05 | 2021-2025 | Takhzyro, Hyqvia, Cuvitru |
| Genzyme Corporation | $730.28 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $715.46 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $607.67 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $373.33 | 2019-2025 | |
| Pfizer INC. | $355.94 | 2019-2025 | |
| Csl Behring | $322.66 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Grifols USA, LLC | $296.47 | 2019-2025 | Xembify, Gamunex-C |
| Pharming Healthcare, INC. | $282.90 | 2021-2024 | Ruconest |
| Optinose US, INC. | $273.18 | 2019-2025 | |
| Amgen INC. | $270.41 | 2019-2025 | Tezspire, Otezla, Repatha |
| Abbvie INC. | $232.81 | 2020-2025 | |
| Lilly USA, LLC | $172.06 | 2019-2025 | Ebglyss, Taltz, Zepbound |
Show all 48 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Jost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.